Concepedia

Publication | Closed Access

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

DOI

816

Citations

28

References

2019

Year

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova,
New England Journal of Medicine

Abstract

Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was associated with longer progression-free survival than chlorambucil-obinutuzumab. (Funded by F. Hoffmann-La Roche and AbbVie; ClinicalTrials.gov number, NCT02242942.).

References

YearCitations

Page 1